London, UK – 12 March 2026 – Avigen Ltd (“the Company”), a privately held Contract Research Organisation developing advanced preclinical immunotherapy R&D services using its proprietary microfluidic platform and Etcembly Ltd, a techbio company leveraging generative AI for the development of…